Repatha® is a fully human monoclonal antibody that binds selectively and with high affinity to circulating PCSK9.1 This
prevents PCSK9 from binding to the LDL receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated
LDLR degradation.1 Increasing liver LDLR levels causes blood LDL-C levels to decrease.1
Discover how Repatha® works
Watch a short animated video to learn more about how PCSK9 inhibition with Repatha® delivers intensive LDL-C
*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl. †25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; LDL-C = Low-density lipoprotein cholesterol; LDLR = LDL receptor; MI = Myocardial
infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
Repatha® (evolocumab) Summary of Product Characteristics. Last revised: 31 March 2021.
Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6. Main paper & Supplementary appendix.